Idiopathic hypereosinophilic syndrome (HES) is a disorder characterized by the sustained overproduction of eosinophils and multiple organ damage. Rheumatologic manifestations of HES are infrequent, but persistent eosinophilia is observed in approximately 10% to 40% of patients with rheumatoid arthritis (RA). This finding may be a result of the RA itself and is often associated with active disease and the presence of extra-articular features. We describe the case of a 48-year-old man affected by HES who subsequently developed RA. Both HES and RA responded rapidly to the corticosteroid and methotrexate therapy. In this patient, the initiation of RA and HES was related, suggesting a common pathogenetic link between these two diseases. (J Rheum Dis 2017;24:165-168)
INTRODUCTION
Idiopathic hypereosinophilic syndrome (HES) is a leukoproliferative disorder characterized by sustained overproduction of eosinophils. Although all organ systems can be affected, dermatological involvement is the most common, followed by pulmonary, gastrointestinal, and cardiac involvement [1] . However, HES manifestations are commonly observed in many other medical conditions, making the initial diagnosis more difficult to establish. The first step is to rule out other conditions that present with similar symptoms. Though reports of late onset HES in patients with rheumatoid arthritis (RA) have been confirmed in several cases, it is still unknown if HES is related to the drugs used for RA or to the disease itself [2, 3] . The patient described in this case was diagnosed with RA during 4 months of follow-up for HES, when he presented with joint symptoms. Our case differs from pre-vious cases that described the onset of HES in longstanding RA cases. To our knowledge, such case is reported for the first time in Korea.
CASE REPORT
In October 2015, a 48-year-old man was admitted with a 3 week history of generalized weakness, cough, and rapidly progressive dyspnea. He described a nonproductive cough, but denied fever, chest pain, changes in weight, or skin lesions. On admission, physical examination revealed bilateral lower extremity edema and facial edema. Laboratory examination revealed leukocytosis (peak 29.5×10 results of the patient were all negative. Chest X-ray was unremarkable. An extensive workup excluded other causes of secondary hypereosinophilia. The results of a bone marrow sample showed normal myeloid blasts, thus ruling out eosinophilia caused by myeloproliferative diseases. A high-resolution computed tomography (HRCT) scan of the lungs revealed subpleural distribution of small hyperdense nodules in the right lower lobe ( Figure 1 ). We performed pulmonary function test and arterial blood gas analysis and found normal results (forced expiratory volume [FEV]1 2.90 L, FEV1/forced vital capacity 70%, PaO2 75.5 mmHg). Upper gastrointestinal endoscopy showed mild uneven mucosal lesions with swelling, while endoscopic biopsies obtained from the stomach and duodenum revealed chronic gastritis with metaplasia and no evidence of eosinophilic infiltration. Electrocardiography and echocardiography showed no abnormal findings. The patient's history did not suggest medication-induced HES. In order to rule out the eosinophilic granulomatous polyangiitis, we checked the level of C-antineutrophil cytoplasmic antibody (ANCA), and P-ANCA. The results were negative.
Consequently, the patient was diagnosed with idiopathic HES based on the presence of marked blood eosinophilia associated with an evidence of eosinophil-induced organ damage, in the absence of other causes of hypereosinophilia such as allergic, parasitic, and malignant disorders. Following the diagnosis of HES, therapy with oral prednisolone (60 mg/d) and antihistamines was initiated. One month after the initiation of therapy, the pulmonary infiltrations disappeared on HRCT. Two months after the presentation, the patient was doing well on 15 mg/d of prednisolone, but any attempts to lower the dose below 10 mg/d resulted in peripheral eosinophilia recurrence.
In February 2016, while the patient was on steroid tapering therapy (15 mg/d), general edema recurred and he complained of worsening pain in both ankles and wrists. This prompted an admission for further evaluation, during which, the recurrence of facial and peripheral edema was also noted. Laboratory examination revealed leukocytosis (peak 20.9×10 3 /μL) and eosinophilia (40.4% eosinophils, peak 8.46×10 3 /μL). The erythrocyte sedimentation rate (ESR) (70 mm/h [normal, 0∼9 mm/h]) and C-reactive protein level (CRP) (37 mg/dL [normal, 0∼5 mg/dL]) were also elevated. A bone scan performed to further evaluate the ankle and wrist pain revealed hyperemic uptake in both joints (Figure 2 ). Rheumatoid factor (RF) level was increased to 78.8 IU/mL and anti-cyclic citrullinated peptide (CCP) antibody level was elevated to 269.2 IU/mL. A diagnosis of RA was made based on the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2010 RA classification criteria [4] . A diagnosis of RA coexisting with HES was made and the patient was started on methotrexate (MTX, 10 mg/wk) and methylprednisolone (30 mg/d). He showed rapid symptomatic improvement after the treatment, with complete resolution of the dyspnea and joint symptoms. White cell count was 10.6×10 3 /μL with 1.6% eosinophils, and the total eosinophil count was 0.5×10 3 /μL. The ESR and CRP levels returned to the normal range. The patient was subsequently treated with methotrexate (10 mg/wk) and low dose oral prednisolone (2.5 mg/d) with satisfactory control of the clinical symptoms.
DISCUSSION
HES is a rare and heterogeneous group of disorders defined as persistent and marked blood eosinophilia (＞1,500 eosinophils/mm 3 for more than 6 consecutive months) associated with evidence of eosinophil-induced organ damage, in the absence of other causes of hypereosinophilia, such as allergic, parasitic, and malignant disorders [1] . The present case did not meet the criteria for persistent eosinophilia, as the time frame was less than 6 months after the initial diagnosis. However, we suspect that the generalized edema and lung abnormalities seen in our patient were clinical features of HES, given the lack of other causes of eosinophilia. Target-organ damage mediated by eosinophils is highly variable among patients, with involvement of skin, heart, lungs, and central and peripheral nervous systems in more than 50% of cases [5] . Eosinophilia may be primary or secondary. Cases of eosinophilia in which an underlying cause has been sought but not found fall into the "idiopathic" category. If the condition is chronic and has led to tissue damage, the term "idiopathic hypereosinophilic syndrome" is used [6] . Secondary eosinophilia is a cytokine-derived (interleukin-5) reactive phenomenon. Worldwide, parasitic diseases are the most common cause, whereas in developed countries, allergic diseases are the most common cause [7] . Although rheumatologic manifestations of HES are infrequent, several previous reports showed HES association with an inflammatory joint disease mimicking RA [3, [8] [9] [10] . Furthermore, Tay [11] described 10 patients from Singapore with acute polyarthritis and marked hypereosinophilia of unknown etiology. He attached the label 'eosinophilic arthritis' to this condition. The articular involvement represented soft tissue and synovial fibrinoid degeneration with eosinophilic infiltration. Brogadir et al. [8] reported a case of articular involvement in HES and suggested that this could be one of a multitude of cases of hand deformity resembling rheumatoid arthritis. In our case, we suspected HES-induced arthritis based on the gradual onset of ankle pain, but since the patient also complained about concomitant knee and wrist pain, we evaluated anti-CCP antibody and RF levels and these findings further supported our diagnosis. In a retrospective study of 45 cases of RA, certain extra-articular manifestations of RA were found to occur more frequently in patients with eosinophilia [3] . Furthermore, in a previous study, HES developed during the course of long-standing RA and was directly associated with an exacerbation of the arthritic condition [6, 12] . The conversion of seronegative into seropositive RA along with the onset of HES during treatment has also been reported [13] . It is, however, not clear whether HES is a consequence of the rheumatoid inflammatory process itself or induced by disease modifying anti-rheumatic drugs. In our patient, HES initially occurred in the absence of joint symptoms and RA was diagnosed after the initiation of HES therapy, and in the presence of newly developed joint symptoms and elevated levels of RF and anti-CCP antibody. Therefore, in this case, it is unlikely that HES was a consequence of the drugs used in the treatment of RA. Therefore, although the precise mechanism is unknown, the possibility of a common pathogenetic link between the two diseases was raised, and the common denominator, the eosinophils, is believed to play a central role [14] .
Because of the rarity of HES, no evidence-based guidelines address its management. Corticosteroids are first-line treatment, with prednisolone with hydroxyurea or interferon alpha as second-line agents. Our patient was treated with disease-modifying antirheumatic drugs including MTX, and these drugs proved to be very efficacious both on articular pathology and on the clinical and laboratory manifestations of HES. These data also suggest the common pathogenetic mechanisms in RA and HES.
SUMMARY
This case differs from preceding cases described in the literature because HES did not develop in a patient who was originally treated for RA, but rather the symptoms of RA developed subsequently to HES. The onset of RA and HES was directly related, implying a common pathogenetic link between these two diseases. This case calls for increased attention to autoimmune diseases such as RA in cases where joint symptoms develop in HES patients.
